D.E. Shaw & Co
ASBP

D.E. Shaw & Co’s Aspire Biopharma ASBP Stock Holding History

D.E. Shaw & Co’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,016
Closed -$12.8M – 4641
2023
Q1 		$12.8M Buy
1,016
+683
+205% +$8.54M 0.01% 1184
2022
Q4 		$4.13M Hold
333
– – ﹤0.01% 2274
2022
Q3 		$4.06M Hold
333
– – ﹤0.01% 2319
2022
Q2 		$3.99M Buy
+333
New +$3.99M ﹤0.01% 2395

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

D.E. Shaw & Co's ASBP Position: Q2 2023 in Review

D.E. Shaw & Co sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 1,016 shares — an estimated $12.8M sold.

D.E. Shaw & Co first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $12.8M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

  • D.E. Shaw & Co reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,016 Aspire Biopharma shares in Q2 2023, an estimated $12.8M.
  • D.E. Shaw & Co first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • D.E. Shaw & Co's Aspire Biopharma position peaked at $12.8M in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.